PATENT CLAIM ANALYSIS

Application Number: 16170764
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-02
Patent Classification: ["514", "04400A"]

Abstract:
Described herein are pseudotyped oncolytic viruses comprising nucleic acids encoding an engager molecule. In some embodiments, the pseudotyped oncolytic viruses comprises nucleic acids encoding an engager molecule and one or more therapeutic molecules. Pharmaceutical compositions containing the pseudotyped oncolytic virus and methods of treating cancer using the pseudotyped oncolytic viruses are further provided herein.

Claim (Index 19):
An oncolytic herpes simplex virus (HSV) comprising a recombinant nucleic acid comprising:\n i) a first nucleic acid sequence encoding a polypeptide comprising a first domain specific for an antigen expressed on an effector cell and a second domain that binds to a tumor antigen expressed on a target cell, wherein the antigen expressed on the effector cell is CD3, and wherein the tumor antigen is CD19 ii) a second nucleic acid sequence encoding an immune modulator polypeptide selected from the group consisting of a cytokine, a costimulatory molecule, an immune checkpoint polypeptide, an anti-angiogenesis factor, and a matrix metalloprotease (MMP).

Metadata:
- Claim Count in Document: 17.0
- Percentile: 97.0
- Lexical Diversity: 1.56757
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15511973', '16132064', '15767076', '15046000', '16161542']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7569128834637137
- 35 USC 102 Novelty (BERT): 0.5123730508238554
- Combined Prediction Score: 0.7324589001997278
- Mean Citation Score: 294.459042
- Max Citation Score: 304.05737
- Similarity Product: 233.8880596401906

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test